LRRK2 and diabetes mellitus: Emerging multimodal biomarkers, genetic risk (e.g., APOE4, LRRK2, TREM2), metabolic status (insulin resistance, diabetes), imaging (amyloid/tau PET, MRI), and fluid omics (CSF proteomics, metabolomics), could be integrated into companion-diagnostic frameworks as in oncology.